November 15, 2024Evergreen TherapeuticsA well-known pharmaceutical enterprise in Shandong ProvinceJuxian PharmaceuticalAnnounce the establishment of a long-term strategic partnership.This strategic cooperation marks the deep integration of both parties in the field of drug research and development. Evergreen Therapeutics will utilize its expertise in artificial intelligence, pharmaceuticals, and clinical technologies to provide comprehensive support for Shandong Yantai Xiyuan Pharmaceutical Factory's new drug development.This collaboration will not only help accelerate the R&D process of new drugs but also promote continuous innovation in the field of innovative medicines for both parties.The cooperation between the two parties will promote the intelligence and precision of drug research and development, improve the efficiency and success rate of drug R&D, and bring more high-quality treatment options to patients.
Mr. Ju-Xian Wang (right), Chairman of Shandong Yantai Xiyuan Pharmaceutical Factory, and Dr. Tao Du (left), Chairman of Evergreen Therapeutics, sign a cooperation agreement at the headquarters of Shandong Yantai Xiyuan Pharmaceutical Factory.Both teams took a group photo at the signing ceremony.
Chairman Wang Juxian of Shandong Yantai Xiyuan Pharmaceutical FactoryIndicates:"The cooperation with Evergreen Therapeutics marks an important step in the intelligent transformation and overall strength enhancement of our company. We look forward to strengthening technical exchanges through this collaboration, leveraging the synergistic advantages of both parties, and jointly overcoming technical challenges. We will focus on innovation-driven development and talent cultivation, aiming to develop more drugs that benefit patients."Dr. Tao Du, Chairman of Evergreen TherapeuticsIndicates:"Evergreen Therapeutics has been committed to applying AI technology to improve the efficiency and success rate of drug clinical development, which has been well validated in our self-developed pipeline. Multiple new molecular pipelines of the company have been successfully approved by the U.S. FDA to enter clinical trials. We look forward to this collaboration with Shandong Yantai Xiyuan Pharmaceutical Factory to jointly promote the application of AI technology in drug development and efficiently develop more drugs that meet clinical needs."The achievement of this strategic cooperation is based on the shared strategic goals and values of both parties, aiming to achieve mutual benefits through complementary advantages. In the future, both parties will continue to deepen their cooperation and jointly explore more cooperation opportunities in various fields, contributing to the development of China's biopharmaceutical industry.
About Shandong Yantai Xiyuan Pharmaceutical FactoryShandong Yantai Xiyuan Pharmaceutical Factory was established in 2009 and is located in Fushan District, Yantai City. The company integrates research, production, and sales, with complete production workshops, advanced production facilities, a supporting pharmaceutical testing center, and a pharmaceutical research and development center. Through technical upgrades in recent years, the company has made significant progress in both Chinese and Western medicine R&D, with 20 outstanding products having received market approval. The company has successively been awarded the provincial title of "Gazelle Enterprise" and possesses a provincial "One Company One Technology Research Center," as well as being named a "Yantai Science and Technology SME," "Outstanding Biopharmaceutical Product Enterprise," "Yantai Biopharmaceutical Industry Integrity Demonstration Unit," and one of the "Top Ten Enterprises" in Yantai’s biopharmaceutical sector.
About Evergreen TherapeuticsEvergreen Therapeutics, based in Shenzhen, is an innovative pharmaceutical company that focuses on the development and application of AI technologies in biotechnology and clinical settings. With branches in Shenzhen and Yantai, China, as well as Maryland, USA, the company’s international team comprises top talents from fields related to AI-driven drug discovery, including clinical medicine, international regulatory laws, chemistry, and computational sciences. Evergreen Therapeutics consistently prioritizes treating diseases with "urgent clinical needs" and focuses on developing first-in-disease novel therapeutics worldwide. The company operates under a dual business model of "self-research + services." On one hand, it engages in the development of differentiated proprietary drugs exclusively within the ophthalmology, vascular, and autoimmune sectors. In other therapeutic areas, the company leverages its unique AI-powered drug discovery platform, combined with expertise in pharmaceutical regulations and clinical processes, to provide clients and partners with comprehensive, one-stop solutions addressing challenges from drug discovery through clinical stages. This includes flexible and efficient R&D solutions and optimal regulatory submission pathway planning.
